Abstract
Lung involvement constitutes nowadays the major cause of morbidity and mortality in scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation. Early diagnosis and treatment of active alveolitis is essential to prevent the deterioration of pulmonary function, improving outcome in SSc patients. The aim of the study was to investigate the effect of 1-year treatment with oral cyclophosphamide (CYC) on the evolution of interstitial lung disease in scleroderma patients with a diagnosis of active alveolitis. An open-label one-arm monocenteric study was conducted on 33 scleroderma patients with active alveolitis—defined as the presence of areas of ‘ground-glass attenuation’ on high-resolution computed tomography and a recent deterioration in lung function—treated with oral CYC 2 mg kg−1 day−1 for 1 year and medium-low dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day). Results showed that diffusing capacity for carbon monoxide (DLco) values remained stable after 6 months of treatment and significantly increased after 12 months (2.06±1.38, 2.21±1.62 and 2.39±1.64 mmol/min/kPa, at baseline/6/12 months, respectively; p<0.001 12th month vs baseline) vital capacity (VC) values slightly increased (i.e. stabilised) in the same time frame (2.46±0.71, 2.41±0.76 and 2.56±0.75 l). Accordingly, the vast majority of our patients (n=29, 87.9%) presented a DLco and/or a VC improvement or stabilisation with respect to baseline. Favourable results were more likely to be observed in patients with a lower Wells’ radiological grade (grade I). In 25 patients followed up for further 12 months after the interruption of therapy, VC and DLco remained stable. Thus, long-term therapy with oral CYC is effective in ameliorating and/or stabilising lung function in scleroderma patients with active alveolitis, with beneficial effects lasting up to 1 year after interruption. The higher efficacy in those patients with an early pulmonary disease stage and a lower radiological grade underlies the importance of an early diagnosis and intervention.
Similar content being viewed by others
References
Silver RM (1991) Clinical aspect of systemic sclerosis (scleroderma). Ann Rheum Dis 50:854–861
Altman RD, Medsger TA Jr, Bloch DA et al (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413
Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444
Harrison NK, Myers AR, Corrin B et al (1991) Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144:706–713
Wells AU, Hansell DM, Corrin B et al (1992) High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47:738–742
Silver RM, Warrick JH, Kinsella MB et al (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844
White B, Moore WC, Wigley FM et al (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 1932:947–954
Pakas I, Ioannidis JP, Malagari K et al (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304
Davas EM, Peppas C, Maragou M et al (1999) Intravenous cyclophosphamide pulse for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461
Giacomelli R, Valentini G, Salsano F et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731–736
Steen VD, Lanz JK, Conte C et al (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290–1296
Varai G, Earle L, Jimenez SA et al (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25:1325–1329
Ǻkesson A, Scheja A, Lundin A et al (1995) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729–735
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
Silver RM, Miller KS, Kinsella MB et al (1990) Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 88:470–476
Wells AU, Hansell DM, Rubens MB et al (1994) Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 150:462–468
American Thoracic Society (1995) Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique—1995 an update. Am J Respir Crit Care Med 152:2185–2198
Goldman HI, Becklake MR (1959) Respiratory function tests. Normal values at median altitudes and the prediction of normal results. Am Rev Respir Dis 79:457–467
Burrows B, Kasik JE, Niden AH et al (1961) Clinical usefulness of the single-breath pulmonary diffusing capacity test. Am Rev Respir Dis 84:789–806
White B, Bauer EA, Goldsmith LA et al (1995) Guidelines for clinical trial in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 38:351–360
Muller NL, Staples CA, Miller RR et al (1987) Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 165:731–734
Gay SE, Kazerooni EA, Toews GB et al (1998) Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 157:1063–1072
Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beretta, L., Caronni, M., Raimondi, M. et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 26, 168–172 (2007). https://doi.org/10.1007/s10067-006-0254-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0254-x